AUTH/2158/8/08: Pharmacist v Sanofi-Aventis (Acomplia reply-paid card fulfilment) – No breach

📅 2008 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2158/8/08
ComplainantPharmacist practitioner
CompanySanofi-Aventis
MedicineAcomplia (rimonabant)
IssueAlleged failure to respond to a reply-paid card request for clinical papers and items (laptop case, USB stick, laser pointer)
Applicable Code year2008
Clause(s) consideredClause 9.1
Panel decisionNo breach of Clause 9.1
AppealAppeal by the complainant; unsuccessful
Complaint received06 August 2008
Case completed13 November 2008
SanctionsNone stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A pharmacist practitioner complained that after returning a reply-paid card for Acomplia (rimonabant), no requested items were delivered after about four weeks.
  • The card (sent after NICE guidance) offered copies of four rimonabant clinical studies and items described as useful to the practice (a laptop case, a USB stick and a laser pointer).
  • The complainant indicated on the card that he did not want to see a representative.
  • Sanofi-Aventis said it had no record of receiving a reply-paid card from the complainant (though it had a record of one returned from a GP at the same practice).
  • Sanofi-Aventis described its fulfilment process: cards returned to an agency, forwarded weekly to representatives; representatives ordered requested materials monthly; typical end-to-end timeframe was 8–12 weeks.
  • The Panel accepted Sanofi-Aventis’ position that the complainant’s card was not received and was assumed lost in the post.
  • The complainant appealed, disputing the “lost in the post” explanation and arguing the company should have rectified the situation.
⚖️

Outcome

  • No breach of the Code was ruled.
  • No breach of Clause 9.1 was ruled by the Panel.
  • The Appeal Board upheld the Panel’s ruling; the appeal was unsuccessful.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training